The mobile phase was methanol : 0.5 % formic acid aqueous solution (8/92, v/v) system in the gradient elution profile at a flow- rate of 0.8 mL/min, methyldopa was used as the internal standard (IS). The retention times of levodopa, benserazide and methyldopa were 3.9, 2.2 and 7.1 min respectively. The tandem MS optimal conditions were analyzed, and hypothetical electrospray ionization ESI(+)- MS/MS fragmentation Angiogenesis inhibitor pattern for levodopa, benserazide, dopamine and methyldopa was illustrated. Quantification was achieved using a positive electrospray ionization (ESI+) interface under multiple reaction monitoring (MRM) condition. No endogenous interferences were found
for levodopa, benserazide and methyldopa, the matrix effects were negligible. The limit of detection (LOD) for levodopa and benserazide were 0.32 and 0.20 ng/mL in plasma, respectively. The calibration curve for levodopa showed linearity in the range 1.28- 1280 ng/mL with a regression coefficient of 0.9997 and the calibration curve for benserazide showed linearity in the range 0.80-800 ng/mL with a regression coefficient of 0.9999. The pharmacokinetics of levodopa and benserazide was studied in Beagle dogs following intragastric administration. The t1/2(beta) were 1.78 +/- 0.24 and
2.28 +/- 0.57 h, the T-max were 0.67 +/- 0.14 and 0.75 +/- 0.00 h, the Cmax were 55.21 +/- 13.92 and 0.02 +/- 0.01 mu g/mL, the AUC(0)-(infinity) were 74.60 +/- 12.16 and 0.04 +/- 0.01 h mu g/mL, the MRT were 1.78 +/- 0.06 and 2.61 +/- 0.39 h for levodopa and https://www.selleckchem.com/screening/kinase-inhibitor-library.html benserazide, respectively. The novel method was validated and suitably applied to measuring of levodopa and benserazide in plasma samples and its oral single dose pharmacokinetics to Beagle dog. Compared with the methods reported in literatures before, the result showed excellent accuracy, specificity and sensitivity, suggesting its applicability to preclinical and clinical pharmacological research.”
“Background: Distraction osteogenesis creates a challenging bone-healing Selleckchem LGX818 environment with protracted demand for cells of the osteoblast lineage. Platelet-derived growth factor-BB (PDGF-BB)
is an osteoblast mitogen and chemotaxin that has been shown to accelerate and/or enhance bone-healing in several preclinical studies. The purpose of the present study was to determine whether recombinant human platelet-derived growth factor-BB (rhPDGF-BB) would have a similar effect on regenerate healing after distraction osteogenesis.
Methods: Unilateral 7-mm mid-diaphyseal femoral lengthening procedures were performed in eighty-three male Sprague-Dawley rats that were separated into five experimental groups. During the distraction period (Days 7 to 28), each animal received a weekly 50-mu L injection of either sodium acetate buffer, bovine collagen dissolved in sodium acetate buffer, or one of three concentrations of rhPDGF-BB (100, 300, or 1000 mu g/mL) into the distraction site.